Entera Bio Files Patent Applications for Inventions that Optimize its Platform Technology for Oral Delivery of Large Molecule Therapeutics
05 mai 2022 08h00 HE
|
Entera Bio Ltd.
— Inventions aim to improve bioavailability and reduce drug costs — — Patent applications include optimized oral delivery of specific molecules for various indications — BOSTON and JERUSALEM, May ...
Entera Bio to Report First Quarter 2022 Financial Results on May 12
28 avr. 2022 08h00 HE
|
Entera Bio Ltd.
BOSTON and JERUSALEM, April 28, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced today it will report...
Entera Bio to Present at 2022 Maxim Virtual Growth Conference
22 mars 2022 08h00 HE
|
Entera Bio Ltd.
BOSTON and JERUSALEM, March 22, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced that the Company...
Entera Bio Reports Financial Results for the Year Ended December 31, 2021
08 mars 2022 06h30 HE
|
Entera Bio Ltd.
— EB613 expected to commence pivotal Phase 3 Osteoporosis trial in 2022 —— New EB612 formulation for Hypoparathyroidism trial planned in 2022 —— Oral delivery technology platform advances with more...
Entera Bio to Report Business and Financial Results for the Year Ended December 31, 2021 on March 8, 2022
03 mars 2022 09h50 HE
|
Entera Bio Ltd.
BOSTON and JERUSALEM, March 03, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced today it will report...
Entera Bio to Present at Aegis Virtual Conference on February 23rd
17 févr. 2022 08h30 HE
|
Entera Bio Ltd.
BOSTON and JERUSALEM, Israel, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced that the...
Entera Bio Announces Successful EB613 End-of-Phase 2 Meeting with FDA: FDA Agrees to Phase 3 Twelve Month Study with Lumbar Spine BMD (bone mineral density) as the Primary Endpoint
04 janv. 2022 08h30 HE
|
Entera Bio Ltd.
BOSTON and JERUSALEM, Israel, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), today announced it has concluded its End-of-Phase 2 meeting with the U.S. Food and Drug...
Entera Bio Reports Third Quarter 2021 Financial Results
10 nov. 2021 08h30 HE
|
Entera Bio Ltd.
‒ Two Presentations at ASBMR, including Late Breaker, on Phase 2 EB613 Clinical Trial Results in Osteoporosis ‒ ‒ Study Sets Stage for Phase 3 registrational trial in 2022 ‒ BOSTON and...
Entera Bio Publishes Key Study Describing its Oral Delivery Technology Platform for Biologic Drugs
28 oct. 2021 08h30 HE
|
Entera Bio Ltd.
‒Study describes a dual mechanism of action approach to oral drug delivery of large molecules, the “Holy Grail” of drug development. ‒Technology is utilized in Entera’s EB613 oral PTH drug for...
Entera Bio Presents Positive Phase 2 6-Month Bone Mineral Density Data for Oral PTH Formulation at Late Breaker ASBMR Conference Session
06 oct. 2021 08h30 HE
|
Entera Bio Ltd.
Increases in lumbar spine, femoral neck and total hip BMD demonstrated with EB613 Linear Dose Responses Seen in Biomarker and Bone Mineral Density Data Pivotal Phase 3 registration study expected to...